MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1159/000553342

Медицинская библиотека · Visceral medicine · 2026

Topical Budesonide for Stricture Prevention following Wide-Field Endoscopic Submucosal Dissection of Superficial Esophageal Neoplasia.

Blasberg Tobias, Wannhoff Andreas, Meiborg Moritz, Richl Johannes, Hiebel Lukas, Mekolli Ardian, Amanzada Ahmad, Ellenrieder Volker, Hochberger Jürgen, Caca Karel, Wedi Edris

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Esophageal stricture (ES) is a frequent and clinically significant adverse event after wide-field endoscopic submucosal dissection (ESD) for superficial esophageal neoplasia. Despite multiple prophylactic strategies, prevention remains challenging, and current steroid-based regimens offer limited efficacy. This study evaluated the efficacy and safety of budesonide orodispersible tablets (BOT) for ES prevention after wide-field ESD.

METHODS

This retrospective, dual-center study evaluated prospectively collected data from patients with superficial esophageal neoplasia undergoing wide-field ESD (≥50% circumferential extent) between August 2020 and August 2024. All patients received BOT (Jorveza® 1 mg twice daily; Dr. Falk Pharma GmbH, Germany) for 4-8 weeks post-ESD. Patients receiving additional stricture-prevention measures were excluded. The primary endpoint was post-ESD stricture. Secondary endpoints included BOT-related adverse events.

RESULTS

Twenty patients (mean age 62.8 ± 10.8 years) underwent ESD with BOT prophylaxis. ES occurred in 35.0% overall - 13.3% after resections involving 50-90% of the esophageal circumference and 100% after circumferential (100%) resections. Patients with strictures had greater circumferential resection extent (85.7% vs. 59.2%; p = 0.036). Four strictures were mild (≤7 dilations) and 3 refractory (≥8). BOT was well tolerated; 2 patients (10.0%) developed asymptomatic esophageal candidiasis, and no systemic steroid-related adverse events occurred.

CONCLUSION

BOT prophylaxis was well tolerated and may reduce strictures after non-circumferential resections; however, its protective effect appears limited in circumferential resections. Combination strategies may be warranted in high-risk patients.

Для цитирования: Blasberg Tobias, Wannhoff Andreas, Meiborg Moritz, Richl Johannes, Hiebel Lukas, Mekolli Ardian, Amanzada Ahmad, Ellenrieder Volker, Hochberger Jürgen, Caca Karel, Wedi Edris. Topical Budesonide for Stricture Prevention following Wide-Field Endoscopic Submucosal Dissection of Superficial Esophageal Neoplasia.. Visceral medicine. 2026. DOI: 10.1159/000553342.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.